038070 — Seoulin Bioscience Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapNeutral

Annual income statement for Seoulin Bioscience Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	R2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	65,085	80,539	104,708	89,569	75,410
Cost of Revenue
Gross Profit	16,566	21,104	24,349	19,921	18,980
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	60,616	74,494	96,024	89,404	75,310
Operating Profit	4,469	6,045	8,684	166	101
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	5,782	20,338	14,029	-1,929	3,556
Provision for Income Taxes
Net Income After Taxes	4,801	15,879	10,565	-2,323	3,140
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	4,893	15,589	10,159	-118	2,914
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	4,893	15,589	10,159	-118	2,914
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	556	1,957	990	166	432
Dividends per Share